EGFR and non-small cell lung carcinoma: Currently, with the widespread use of genetic testing technology, it is recommended to screen for EGFR-mutations in NSCLC patients with BMs and treat them with third-generation EGFR-TKIs, which have better blood–brain barrier penetrability and better efficacy [99].